世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
内分泌検査市場。世界の産業動向、シェア、サイズ、成長、機会、および2021-2026年の予測Endocrine Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global endocrine testing market reached a value of US$ 10 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.7% during 2021-2026. Keeping in mind the uncert... もっと見る
サマリーThe global endocrine testing market reached a value of US$ 10 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient. The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing’s disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients. Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global endocrine testing market, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, test type, technology and end use. Breakup by Test Type: Thyroid Test Insulin Test Human Chorionic Gonadotropin Test Prolactin Test Luteinizing Hormone Test Progesterone Test Others Breakup by Technology: Immunoassay Tandem Mass Spectroscopy Sensor Technology LC-MS Others Breakup by End Use: Hospitals Ambulatory Care Centers Clinical Laboratories Others Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., BioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens Aktiengesellschaft) and Thermo Fisher Scientific Inc. The global endocrine testing market reached a value of US$ 10 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient. The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing’s disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients. Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global endocrine testing market, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, test type, technology and end use. Breakup by Test Type: Thyroid Test Insulin Test Human Chorionic Gonadotropin Test Prolactin Test Luteinizing Hormone Test Progesterone Test Others Breakup by Technology: Immunoassay Tandem Mass Spectroscopy Sensor Technology LC-MS Others Breakup by End Use: Hospitals Ambulatory Care Centers Clinical Laboratories Others Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., BioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens Aktiengesellschaft) and Thermo Fisher Scientific Inc. Key Questions Answered in This Report: How has the global endocrine testing market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global endocrine testing market? What are the key regional markets? What is the breakup of the market based on the test type? What is the breakup of the market based on the technology? What is the breakup of the market based on the end use? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global endocrine testing market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Endocrine Testing Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Test Type 6.1 Thyroid Test 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Insulin Test 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Human Chorionic Gonadotropin Test 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Prolactin Test 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Luteinizing Hormone Test 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Progesterone Test 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Technology 7.1 Immunoassay 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Tandem Mass Spectroscopy 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Sensor Technology 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 LC-MS 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by End Use 8.1 Hospitals 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Ambulatory Care Centers 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Clinical Laboratories 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbott Laboratories 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Agilent Technologies Inc. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Bio-Rad Laboratories Inc. 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 BioMerieux SA 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis 14.3.5 DiaSorin S.p.A. 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 F. Hoffmann-La Roche AG (Roche Holding AG) 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 SWOT Analysis 14.3.7 Laboratory Corporation of America Holdings 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.7.4 SWOT Analysis 14.3.8 Quest Diagnostics Incorporated 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Siemens Healthineers AG (Siemens Aktiengesellschaft) 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis 14.3.10 Thermo Fisher Scientific Inc. 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis
SummaryThe global endocrine testing market reached a value of US$ 10 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient. The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing’s disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients. Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global endocrine testing market, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, test type, technology and end use. Breakup by Test Type: Thyroid Test Insulin Test Human Chorionic Gonadotropin Test Prolactin Test Luteinizing Hormone Test Progesterone Test Others Breakup by Technology: Immunoassay Tandem Mass Spectroscopy Sensor Technology LC-MS Others Breakup by End Use: Hospitals Ambulatory Care Centers Clinical Laboratories Others Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., BioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens Aktiengesellschaft) and Thermo Fisher Scientific Inc. The global endocrine testing market reached a value of US$ 10 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient. The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing’s disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients. Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global endocrine testing market, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, test type, technology and end use. Breakup by Test Type: Thyroid Test Insulin Test Human Chorionic Gonadotropin Test Prolactin Test Luteinizing Hormone Test Progesterone Test Others Breakup by Technology: Immunoassay Tandem Mass Spectroscopy Sensor Technology LC-MS Others Breakup by End Use: Hospitals Ambulatory Care Centers Clinical Laboratories Others Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., BioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens Aktiengesellschaft) and Thermo Fisher Scientific Inc. Key Questions Answered in This Report: How has the global endocrine testing market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global endocrine testing market? What are the key regional markets? What is the breakup of the market based on the test type? What is the breakup of the market based on the technology? What is the breakup of the market based on the end use? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global endocrine testing market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Endocrine Testing Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Test Type 6.1 Thyroid Test 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Insulin Test 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Human Chorionic Gonadotropin Test 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Prolactin Test 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Luteinizing Hormone Test 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Progesterone Test 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Technology 7.1 Immunoassay 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Tandem Mass Spectroscopy 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Sensor Technology 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 LC-MS 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by End Use 8.1 Hospitals 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Ambulatory Care Centers 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Clinical Laboratories 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbott Laboratories 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Agilent Technologies Inc. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Bio-Rad Laboratories Inc. 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 BioMerieux SA 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis 14.3.5 DiaSorin S.p.A. 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 F. Hoffmann-La Roche AG (Roche Holding AG) 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 SWOT Analysis 14.3.7 Laboratory Corporation of America Holdings 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.7.4 SWOT Analysis 14.3.8 Quest Diagnostics Incorporated 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Siemens Healthineers AG (Siemens Aktiengesellschaft) 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis 14.3.10 Thermo Fisher Scientific Inc. 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（産業機械）の最新刊レポート
IMARC Services Private Limited.社のその他分野での最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/26 10:26 155.24 円 162.59 円 197.14 円 |
